EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source saysBRUSSELS/LONDON, Nov 22 (Reuters) - EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent CTLT.N, a person with direct knowledge of the matter said on Friday.
Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk NOVOb.CO, whose profits from blockbuster weight-loss drug Wegovy has made it Europe's most valuable company by market value.
(Reporting by Foo Yun Chee in Brussels and Maggie Fick in London; Editing by Louise Heavens)
((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments